HK Stock Market Move | Biocytogen Pharmaceuticals-B (02315) rises over 10% as dual antibody ADC advances overseas development; preclinical CRO and model mouse indicators show an upward trend.

Biocytogen Pharmaceuticals-B (02315) surged over 10%, and as of the time of writing, it is up 10.39%, trading at HKD 57.9, with a turnover of HKD 80.2846 million. In terms of news, Biocytogen Pharmaceuticals announced last month that it had signed a global strategic cooperation agreement with Whitehawk Therapeutics, Inc., covering multiple bispecific antibody-drug conjugate (BsADC) research and development projects. The two parties will jointly advance a diversified new generation of therapeutic product pipelines. It is reported that it took only about four months from the formal start of cooperation to the completion of the agreement signing. Shenwan Hongyuan Group stated that the company's model animal and preclinical CRO business has maintained a strong growth trend for years, and it has established in-depth and close cooperation with leading global innovative pharmaceutical companies. With high barriers combined with industry dividends, its market share is expected to continue to rise. In addition, the antibody business of the AI + RenMice platform is accelerating realization, and the platform's value and research and development conversion are gradually becoming apparent.